PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
61 hedge funds and large institutions have $95.8M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
11% more funds holding
Funds holding: 55 → 61 (+6)
15% less capital invested
Capital invested by funds: $113M → $95.8M (-$17.3M)
40% less call options, than puts
Call options by funds: $97K | Put options by funds: $162K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.54M |
| 2 |
EP
Eversept Partners
New York
|
+$1M |
| 3 |
CCM
CAAS Capital Management
New York
|
+$878K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$730K |
| 5 |
O
OrbiMed
New York
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$3.33M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.72M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$692K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$339K |
| 5 |
JP Morgan Chase
New York
|
-$256K |
PHAS Hedge Fund Activity: Q3 2021 in Review
61 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q3 2021, worth a combined $95.8M — down 15% from $113M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PHAS positions and 6 closed out — a net gain of 7 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was Candriam SCA, adding an estimated $1.54M. The largest seller was Endurant Capital Management, cutting an estimated $3.33M.
- 61 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q3 2021, up from 55 in Q2 2021.
- Funds reported $95.8M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 15% quarter-over-quarter.
- 13 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +7 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Candriam SCA, an estimated $1.54M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Endurant Capital Management, an estimated $3.33M sold.
Based on aggregated 13F filings for Q3 2021.